With the U.S. FDA go-ahead Feb. 2 for GSK plc’s oral daprodustat for anemia in patients with chronic kidney disease (CKD), the picture brightened for would-be competitors in the hypoxia-inducible ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Let's start with what causes anemia of ...

Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD. The cardiac and kidney-related ...

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States. The FDA has approved daprodustat (Jesduvroq, GSK) for the ...

Please provide your email address to receive an email when new articles are posted on . During the last 3 decades, only one class of drugs – erythropoiesis-stimulating agents – has been available to ...

Akebia's Vafseo, a HIF-PH inhibitor for DD-CKD anemia, faces skepticism despite FDA approval due to safety concerns. Market skepticism towards HIF-PH inhibitors, evidenced by GSK's hesitance in Europe ...

Explore the potential of CKD drug ISM4808 and its role in treating chronic kidney disease through innovative research.

Chronic kidney disease (CKD) is frequently complicated by anaemia, predominantly due to an inadequate production of erythropoietin combined with disruptions in iron metabolism and chronic inflammation ...

TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO ...

Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD. The cardiac and kidney-related ...